INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA

H Ludwig; K Weisel; MT Petrucci; X Leleu; AM Cafro; M Kropff; Richard Greil; N Zojer; T Dummler; A Kruschinski; K Riecke; R Foa; I Yakoub-Agha; M Engelhardt

INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA

H Ludwig, K Weisel, MT Petrucci, X Leleu, AM Cafro, M Kropff, Richard Greil, N Zojer, T Dummler, A Kruschinski, K Riecke, R Foa, I Yakoub-Agha, M Engelhardt

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › published Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	115-116
Journal	HAEMATOLOGICA
Volume	99
Publication status	Published - 2014
Event	19th Congress of the European-Hematology-Association - Milan, ITALY Duration: 12 Jun 2014 → 15 Jun 2014

Cite this

Ludwig, H., Weisel, K., Petrucci, MT., Leleu, X., Cafro, AM., Kropff, M., Greil, R., Zojer, N., Dummler, T., Kruschinski, A., Riecke, K., Foa, R., Yakoub-Agha, I., & Engelhardt, M. (2014). INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA. HAEMATOLOGICA , 99, 115-116.

Ludwig, H ; Weisel, K ; Petrucci, MT et al. / INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA. In: HAEMATOLOGICA 2014 ; Vol. 99. pp. 115-116.

@article{8a724d873fee4becb99977bc8e916f6f,

title = "INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA",

author = "H Ludwig and K Weisel and MT Petrucci and X Leleu and AM Cafro and M Kropff and Richard Greil and N Zojer and T Dummler and A Kruschinski and K Riecke and R Foa and I Yakoub-Agha and M Engelhardt",

year = "2014",

language = "English",

volume = "99",

pages = "115--116",

journal = "HAEMATOLOGICA ",

issn = "0390-6078",

note = "19th Congress of the European-Hematology-Association ; Conference date: 12-06-2014 Through 15-06-2014",

}

Ludwig, H, Weisel, K, Petrucci, MT, Leleu, X, Cafro, AM, Kropff, M, Greil, R, Zojer, N, Dummler, T, Kruschinski, A, Riecke, K, Foa, R, Yakoub-Agha, I & Engelhardt, M 2014, 'INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA', HAEMATOLOGICA , vol. 99, pp. 115-116.

INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA. / Ludwig, H; Weisel, K; Petrucci, MT et al.
In: HAEMATOLOGICA , Vol. 99, 2014, p. 115-116.

Research output: Contribution to journal › published Abstract (Journal) › peer-review

TY - JOUR

T1 - INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA

AU - Ludwig, H

AU - Weisel, K

AU - Petrucci, MT

AU - Leleu, X

AU - Cafro, AM

AU - Kropff, M

AU - Greil, Richard

AU - Zojer, N

AU - Dummler, T

AU - Kruschinski, A

AU - Riecke, K

AU - Foa, R

AU - Yakoub-Agha, I

AU - Engelhardt, M

PY - 2014

Y1 - 2014

M3 - published Abstract (Journal)

SN - 0390-6078

VL - 99

SP - 115

EP - 116

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

T2 - 19th Congress of the European-Hematology-Association

Y2 - 12 June 2014 through 15 June 2014

ER -

Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Kropff M et al. INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA. HAEMATOLOGICA . 2014;99:115-116.